Healthtech Startup Avammune Secures $12 Million to Drive Next-Gen Immune Modulation Therapies
Prime Highlights : Avammune Therapeutics secures $12 million in capital from Capital 2B. Capital to develop low-cost oral drugs for cancer and autoimmune disease. Key Facts : Avammune's platform leverages…